Ignite Creation Date:
2024-05-06 @ 12:50 AM
Last Modification Date:
2024-10-26 @ 10:55 AM
Study NCT ID:
NCT01670500
Status:
COMPLETED
Last Update Posted:
2022-05-25
First Post:
2012-08-16
Brief Title:
Cisplatin vs DoxorubicinCyclophosphamide in BrCa
Sponsor:
Beth Israel Deaconess Medical Center
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
12-258
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Beth Israel Deaconess Medical Center
Lead Sponsor Class:
OTHER
Responsible Party:
Nadine Tung MD
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None